Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient.

Abstract:

:We report on a schizophrenic patient whose tardive dystonia, delusions, and auditory hallucinations showed remarkable concurrent improvement after replacing haloperidol with risperidone. The present finding suggests that the 5-hydroxytryptamine-2 (5-HT2) antagonistic action of risperidone has brought about the improvement in tardive dystonia. The 5-HT2 antagonistic action of risperidone, in addition to its dopamine antagonistic action, may have also lessened psychotic symptoms in the current case.

journal_name

Clin Neuropharmacol

authors

Yoshida K,Higuchi H,Hishikawa Y

subject

Has Abstract

pub_date

1998-01-01 00:00:00

pages

68-9

issue

1

eissn

0362-5664

issn

1537-162X

journal_volume

21

pub_type

杂志文章
  • Severe weight gain induced by combination treatment with risperidone and paroxetine.

    abstract::Successful combination therapy with atypical antipsychotics and selective serotonin reuptake inhibitors has been reported for several psychiatric conditions. However, great attention should be paid to the possible adverse effects. In this retrospective chart review, we focused on the drug-drug interaction of paroxetin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200209000-00009

    authors: Fukui H,Murai T

    更新日期:2002-09-01 00:00:00

  • Diagnosis and assessment of age-associated memory impairment.

    abstract::Age-associated memory impairment (AAMI) is a diagnostic term applied to healthy persons greater than 50 years of age who have experienced a gradual decline in memory that lies within the boundaries of normality. Although the behavioral deficits associated with AAMI are modest in comparison to those associated with dem...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199013003-00009

    authors: Crook TH,Larrabee GJ,Youngjohn JR

    更新日期:1990-01-01 00:00:00

  • The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

    abstract:INTRODUCTION:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals wit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31820d6699

    authors: Dang D,Cunnington D,Swieca J

    更新日期:2011-03-01 00:00:00

  • The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury.

    abstract:OBJECTIVES:To determine the effects of treatment with donepezil on cortical metabolism in patients with traumatic brain injury using F-fluorodeoxyglucose positron emission tomography. METHODS:Twenty-six patients with cognitive impairment after traumatic brain injury were enrolled and randomly assigned into the donepez...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0B013E31816F1BC1

    authors: Kim YW,Kim DY,Shin JC,Park CI,Lee JD

    更新日期:2009-03-01 00:00:00

  • Astroglial cells: glucocorticoid target cells in the brain.

    abstract::Glutamine synthetase (GS), an enzyme localized in astroglial cells in the brain, is directly implicated in brain detoxification. An ontogenic study of GS activity was performed in homogenates from four distinct brain areas in comparison with the respective astrocytes obtained in primary cultures. GS was induced by hyd...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Tardy M,Rolland B,Fages C,Caldani M

    更新日期:1984-01-01 00:00:00

  • Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.

    abstract::Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200111000-00006

    authors: Giménez-Roldán S,Esteban EM,Mateo D

    更新日期:2001-11-01 00:00:00

  • Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.

    abstract:OBJECTIVES:Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS:One hundred thirty...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0000000000000045

    authors: Song J,Kim SW,Hong HJ,Lee MG,Lee BW,Choi TK,Lee SH,Yook KH

    更新日期:2014-09-01 00:00:00

  • Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.

    abstract:OBJECTIVES:Aripiprazole and ziprasidone are 2 antipsychotic medications that are relatively devoid of the metabolic adverse effects associated with the second-generation antipsychotics. This study aimed to evaluate the effectiveness of switching to ziprasidone in patients who had insufficient response or intolerance to...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0b013e3181d52b85

    authors: Kim SW,Shin IS,Kim JM,Bae KY,Yang SJ,Yoon JS

    更新日期:2010-05-01 00:00:00

  • Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report.

    abstract::The selective estrogen receptor modulator, tamoxifen, is extensively used for the endocrine treatment of all stages of hormone receptor-positive breast cancer. Tamoxifen is a mainly inactive prodrug, necessitating metabolism by the cytochrome P450 (CYP450) pathway, predominantly the Cytochrome P450 2D6 (CYP2D6), into ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000009

    authors: De Berardis D,Brucchi M,Serroni N,Valchera A,Fornaro M,Mazza M,Martinotti G,Di Giannantonio M

    更新日期:2014-01-01 00:00:00

  • Serotonin Syndrome Following Combined Administration of Dopaminergic and Noradrenergic Agents in a Patient With Akinetic Mutism After Frontal Intracerebral Hemorrhage: A Case Report.

    abstract:BACKGROUND:Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000220

    authors: Jeon DG,Kim YW,Kim NY,Park JH

    更新日期:2017-07-01 00:00:00

  • Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys.

    abstract::In rodents, serotonin (5-HT) antagonists counteract behavioral and biochemical effects of neuroleptic drugs. Therefore, we have studied the effect of different 5-HT drugs and one anticholinergic drug in acute dystonia in five cebus monkeys chronically treated with haloperidol. Acute dystonia induced by subcutaneous in...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198602000-00010

    authors: Povlsen UJ,Noring U,Laursen AL,Korsgaard S,Gerlach J

    更新日期:1986-01-01 00:00:00

  • Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study.

    abstract:BACKGROUND:Introduction of old and new generations of antipsychotics leads to significant improvements in the positive symptoms of schizophrenia. However, negative symptoms remain refractory to conventional trials of antipsychotic therapy. Recently, there were several open clinical human trials with curcumin. Curcumin ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0000000000000344

    authors: Miodownik C,Lerner V,Kudkaeva N,Lerner PP,Pashinian A,Bersudsky Y,Eliyahu R,Kreinin A,Bergman J

    更新日期:2019-07-01 00:00:00

  • Bupropion Hydrochloride Sustained Release and Diurnal Enuresis: A Previously Unreported Adverse Effect.

    abstract::Bupropion hydrochloride (HCl) is an antidepressant that has many different biological targets, acting as both a norepinephrine-dopamine reuptake inhibitor as well as a nicotinic antagonist. This second-generation antidepressant is available in 3 bioequivalent formulations: immediate release, sustained release, and ext...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000364

    authors: Schwitalla TA,Patel RA,Catalano G,Nirmalani-Gandhy A

    更新日期:2019-11-01 00:00:00

  • The reversibility of "permanent" tardive dyskinesia.

    abstract::Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198406000-00006

    authors: Klawans HL,Tanner CM,Barr A

    更新日期:1984-01-01 00:00:00

  • Reboxetine addition in patients with mirtazapine-resistant depression: a case series.

    abstract:OBJECTIVES:Treatment-resistant depression is a common occurrence in clinical practice as well as combination treatment with 2 different antidepressants. In the present case series, we study the effectiveness of the addition of reboxetine, during 12 weeks, to 14 outpatients diagnosed with major depressive disorder, acco...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.WNF.0000228211.19818.14

    authors: López-Muñoz F,Rubio G,Alamo C,García-García P,Pardo A

    更新日期:2006-07-01 00:00:00

  • Paroxysmal dystonia responsive to anticholinergic drugs.

    abstract::A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198708000-00007

    authors: Micheli F,Fernandez Pardal M,de Arbelaiz R,Lehkuniec E,Giannaula R

    更新日期:1987-08-01 00:00:00

  • Lack of effect of methylphenidate on serum growth hormone (GH), GH-binding protein, and insulin-like growth factor I.

    abstract::The aim of this study was to assess the growth hormone (GH) axis in methylphenidate (MPH)-treated and untreated boys with attention-deficit and hyperactivity disorder (ADHD), by evaluating serum GH, GH-binding protein (GHBP) activity, and insulin-like growth factor I (IGF-I) levels as compared to age-matched normal co...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199706000-00011

    authors: Toren P,Silbergeld A,Eldar S,Laor N,Wolmer L,Koren S,Weitz R,Inbar D,Reiss A,Eshet R,Weizman R

    更新日期:1997-06-01 00:00:00

  • Relief of intractable posthypoxic myoclonus after administration of agomelatine.

    abstract::Chronic posthypoxic myoclonus is characterized by myoclonic jerks that are specifically triggered by action. It is a rare but devastating sequela of hypoxic encephalopathy. We report a 42-year-old female patient with treatment-resistant chronic posthypoxic myoclonus, which improved with administration of the drug agom...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182613e06

    authors: González de la Aleja J,Saiz-Díaz RA,De la Peña P

    更新日期:2012-09-01 00:00:00

  • Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.

    abstract::Duloxetine is a serotonin-noradrenaline reuptake inhibitor that is effective in the treatment of major depressive disorder (MDD) and chronic pain. The safety of duloxetine has been shown by many previous studies. We report a patient who experienced visual hallucinations after taking duloxetine. The patient experienced...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182a124cb

    authors: Tomita T,Yasui-Furukori N,Kaneko S

    更新日期:2013-09-01 00:00:00

  • Cyclosporine A neurotoxicity among bone marrow transplant recipients.

    abstract::Cyclosporine A (CsA) neurotoxicity is an iatrogenic disease with significant morbidity and occasional mortality. We retrospectively reviewed the cases of CsA neurotoxicity among bone marrow transplant recipients at our institution, and summarized the current literature on the subject. The neurologic presentation is va...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199903000-00001

    authors: Shah AK

    更新日期:1999-03-01 00:00:00

  • Effects of terguride in patients with Huntington's disease.

    abstract::trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary mov...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198910000-00008

    authors: Stocchi F,Carta A,Berardelli A,Antonini A,Argenta M,Formica A,Agnoli A

    更新日期:1989-10-01 00:00:00

  • Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.

    abstract::Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199508000-00009

    authors: Rosse RB,Kendrick K,Tsui LC,Fay-McCarthy M,Collins JP Jr,Rosenberg P,Wyatt RJ,Deutsch SI

    更新日期:1995-08-01 00:00:00

  • The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.

    abstract::We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers. Single increasing oral doses of entacapone (50-400 mg) were administered concomitantly with a single oral dose of l...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199304000-00007

    authors: Keränen T,Gordin A,Harjola VP,Karlsson M,Korpela K,Pentikäinen PJ,Rita H,Seppälä L,Wikberg T

    更新日期:1993-04-01 00:00:00

  • Color vision in Parkinson's disease: missing influence of amantadine sulphate.

    abstract::In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199510000-00009

    authors: Büttner T,Kuhn W,Müller T,Patzold T,Przuntek H

    更新日期:1995-10-01 00:00:00

  • Place of dexfenfluramine in the management of obesity.

    abstract::The treatment of obesity remains a puzzling challenge because long-term maintenance of weight loss--one of the most suitable goals--is rarely achieved with conventional methods. Among the theoretical measures able to maintain a permanent and bearable constraint to obtain the maintenance of weight loss is long-term (li...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Guy-Grand BJ

    更新日期:1988-01-01 00:00:00

  • Aggression in children treated with clobazam for epilepsy.

    abstract::Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-199408000-00004

    authors: Sheth RD,Goulden KJ,Ronen GM

    更新日期:1994-08-01 00:00:00

  • Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration.

    abstract::In nine patients with orthostatic hypotension due to multiple system atrophy, the effects of octreotide (100 micrograms s.c.), a somatostatin analogue, on blood pressure (BP), heart rate (HR), and norepinephrine (NE) plasma levels after 60 degrees head up tilt test were evaluated by a randomly controlled study. Octreo...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199502000-00012

    authors: Bordet R,Benhadjali J,Destée A,Belabbas A,Libersa C

    更新日期:1995-02-01 00:00:00

  • A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.

    abstract::Botulinum toxin A (BTA) is considered an effective treatment of cervical dystonia. The aim of this prospective, randomized, double-blind study was to compare Botox and Prosigne, a BTA of Chinese origin, with a view to establish the safety, the efficacy, and the equivalence of doses of the 2 formulations in the treatme...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/WNF.0b013e3181c46f48

    authors: Quagliato EM,Carelli EF,Viana MA

    更新日期:2010-01-01 00:00:00

  • Clinical implications of sustained dopaminergic stimulation.

    abstract::Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Stocchi F,Patsalos PN,Berardelli A,Barbato L,Bonamartini A,Manfredi M,Ruggieri S

    更新日期:1994-01-01 00:00:00

  • Treatment of Tourette's syndrome with calcium antagonists.

    abstract::Six males and one female with chronic tic disorders, whose ages ranged from 12 to 31 years, were evaluated before treatment, after 1 month on placebo, after a single 10 mg nifedipine dose (three patients), and monthly while on flunarizine 10-15 mg (mean dose of 13 mg). None of the patients receiving nifedipine improve...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-199002000-00008

    authors: Micheli F,Gatto M,Lekhuniec E,Mangone C,Fernandez Pardal M,Pikielny R,Casas Parera I

    更新日期:1990-02-01 00:00:00